Abstract
OPINION article Front. Oncol., 03 February 2014Sec. Hematologic Malignancies https://doi.org/10.3389/fonc.2014.00017
Highlights
Accurate clinicobiological evaluation, an evidence-based approach, and identification of potential biomarkers are definitely warranted to delineate the best approach in a given case
It is known that the most cases of chronic myeloid leukemia (CML) are characterized by a BCR–ABL fusion protein originating from the t(9;22) chromosomal translocation
Cases of CML with breakpoints in other regions are seen in other regions, namely minor (m-bcr) and micro (μ-bcr) bcr region, but to date, these cases are few in number
Summary
Accurate clinicobiological evaluation, an evidence-based approach, and identification of potential biomarkers are definitely warranted to delineate the best approach in a given case. The therapeutic landscape of chronic myeloid leukemia (CML) has changed dramatically in the last decade [1]. The availability of imatinib mesylate, a tyrosine kinase inhibitor (TKI) targeting BCR–ABL, has led to profound and durable remissions in the majority of patients.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
